EGFR and neoplasm: Although VM inhibition was seen in vitro with Fc-E-P125A, which does not target EGFR (Supplementary Figure S2C), αEGFR-E-P125A demonstrated greater efficacy against EGFR+ MDA-MB-468 xenografts than Fc-E-P125A in vivo (Figure 4A), suggesting that EGFR targeting is needed for optimal anti-tumor efficacy.